Tirzepatide, a dual GLP-1 and glucose-dependent insulinotropic peptide (GIP) receptor agonist appears to induce even greater weight loss than semaglutide [48] but has not been evaluated in patients with PCOS. The gene discussed is GLP1R; the disease is polycystic ovary syndrome.